The Emerging Applications of Nanotechnology in Neuroimaging: A Comprehensive Review

Overview

Journal Front Bioeng Biotechnol

Date 2022 Jul 25

PMID 35875504

Authors

Khunza Faiz

Fred C Lam

Jay Chen

Ekkehard M Kasper

Fateme Salehi

Affiliations

Soon will be listed here.

Abstract

Neuroimaging modalities such as computer tomography and magnetic resonance imaging have greatly improved in their ability to achieve higher spatial resolution of neurovascular and soft tissue neuroanatomy, allowing for increased accuracy in the diagnosis of neurological conditions. However, the use of conventional contrast agents that have short tissue retention time and associated renal toxicities, or expensive radioisotope tracers that are not widely available, continue to limit the sensitivity of these imaging modalities. Nanoparticles can potentially address these shortcomings by enhancing tissue retention and improving signal intensity in the brain and neural axis. In this review, we discuss the use of different types of nanotechnology to improve the detection, diagnosis, and treatment of a wide range of neurological diseases.

Citing Articles

The reprotoxic adverse side effects of neurogenic and neuroprotective drugs: current use of human organoid modeling as a potential alternative to preclinical models.

Abady M, Jeong J, Kwon H, Assiri A, Cho J, Saadeldin I Front Pharmacol. 2024; 15:1412188.

PMID: 38948466 PMC: 11211546. DOI: 10.3389/fphar.2024.1412188.

Editorial: Nano-Imaging in Translational Cancer Medicine.

Lam F Front Bioeng Biotechnol. 2022; 10:969430.

PMID: 35935484 PMC: 9355474. DOI: 10.3389/fbioe.2022.969430.

References

Surmeier D, Obeso J, Halliday G . Selective neuronal vulnerability in Parkinson disease. Nat Rev Neurosci. 2017; 18(2):101-113. PMC: 5564322. DOI: 10.1038/nrn.2016.178. View

Khanbabaie R, Jahanshahi M . Revolutionary impact of nanodrug delivery on neuroscience. Curr Neuropharmacol. 2013; 10(4):370-92. PMC: 3520046. DOI: 10.2174/157015912804143513. View

Chen J, Pan H, Lanza G, Wickline S . Perfluorocarbon nanoparticles for physiological and molecular imaging and therapy. Adv Chronic Kidney Dis. 2013; 20(6):466-78. PMC: 4074885. DOI: 10.1053/j.ackd.2013.08.004. View

. 2014 Alzheimer's disease facts and figures. Alzheimers Dement. 2014; 10(2):e47-92. DOI: 10.1016/j.jalz.2014.02.001. View

Li T, Murphy S, Kiselev B, Bakshi K, Zhang J, Eltahir A . A New Interleukin-13 Amino-Coated Gadolinium Metallofullerene Nanoparticle for Targeted MRI Detection of Glioblastoma Tumor Cells. J Am Chem Soc. 2015; 137(24):7881-8. DOI: 10.1021/jacs.5b03991. View

Miller S, Tummers W, Teraphongphom N, van den Berg N, Hasan A, Ertsey R . First-in-human intraoperative near-infrared fluorescence imaging of glioblastoma using cetuximab-IRDye800. J Neurooncol. 2018; 139(1):135-143. PMC: 6031450. DOI: 10.1007/s11060-018-2854-0. View

Khandhar A, Keselman P, Kemp S, Ferguson R, Goodwill P, Conolly S . Evaluation of PEG-coated iron oxide nanoparticles as blood pool tracers for preclinical magnetic particle imaging. Nanoscale. 2017; 9(3):1299-1306. PMC: 5316483. DOI: 10.1039/c6nr08468k. View

Chen L, Zhang B, Toborek M . Autophagy is involved in nanoalumina-induced cerebrovascular toxicity. Nanomedicine. 2012; 9(2):212-21. PMC: 3482418. DOI: 10.1016/j.nano.2012.05.017. View

Heid S, Unterweger H, Tietze R, Friedrich R, Weigel B, Cicha I . Synthesis and Characterization of Tissue Plasminogen Activator-Functionalized Superparamagnetic Iron Oxide Nanoparticles for Targeted Fibrin Clot Dissolution. Int J Mol Sci. 2017; 18(9). PMC: 5618486. DOI: 10.3390/ijms18091837. View

10.

Stark D, Weissleder R, Elizondo G, Hahn P, Saini S, TODD L . Superparamagnetic iron oxide: clinical application as a contrast agent for MR imaging of the liver. Radiology. 1988; 168(2):297-301. DOI: 10.1148/radiology.168.2.3393649. View

11.

Ferreira G, Cardoso E, Vuolo F, Galant L, Michels M, Goncalves C . Effect of acute and long-term administration of gold nanoparticles on biochemical parameters in rat brain. Mater Sci Eng C Mater Biol Appl. 2017; 79:748-755. DOI: 10.1016/j.msec.2017.05.110. View

12.

Mason S, McShane R, Ritchie C . Diagnostic tests for Alzheimer's disease: rationale, methodology, and challenges. Int J Alzheimers Dis. 2010; 2010. PMC: 2929623. DOI: 10.4061/2010/972685. View

13.

Booij J, Speelman J, Horstink M, Wolters E . The clinical benefit of imaging striatal dopamine transporters with [123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism. Eur J Nucl Med. 2001; 28(3):266-72. DOI: 10.1007/s002590000460. View

14.

Hendricks B, Cohen-Gadol A, Miller J . Novel delivery methods bypassing the blood-brain and blood-tumor barriers. Neurosurg Focus. 2015; 38(3):E10. DOI: 10.3171/2015.1.FOCUS14767. View

15.

Anselmo A, Mitragotri S . Nanoparticles in the clinic. Bioeng Transl Med. 2018; 1(1):10-29. PMC: 5689513. DOI: 10.1002/btm2.10003. View

16.

Sharma A, Schultz J, Prior J, Rath N, Mirica L . Coordination Chemistry of Bifunctional Chemical Agents Designed for Applications in Cu PET Imaging for Alzheimer's Disease. Inorg Chem. 2017; 56(22):13801-13814. PMC: 5698879. DOI: 10.1021/acs.inorgchem.7b01883. View

17.

Sirsi S, Borden M . Microbubble Compositions, Properties and Biomedical Applications. Bubble Sci Eng Technol. 2010; 1(1-2):3-17. PMC: 2889676. DOI: 10.1179/175889709X446507. View

18.

Gabizon A, Shmeeda H, Zalipsky S . Pros and cons of the liposome platform in cancer drug targeting. J Liposome Res. 2006; 16(3):175-83. DOI: 10.1080/08982100600848769. View

19.

Li S, Lin C, Wei K, Huang C, Hsu P, Liu H . Non-invasive screening for early Alzheimer's disease diagnosis by a sensitively immunomagnetic biosensor. Sci Rep. 2016; 6:25155. PMC: 4844990. DOI: 10.1038/srep25155. View

20.

Harisinghani M, Barentsz J, Hahn P, Deserno W, Tabatabaei S, van de Kaa C . Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med. 2003; 348(25):2491-9. DOI: 10.1056/NEJMoa022749. View